Equities analysts predict that Nevro Corp (NYSE:NVRO) will announce earnings of ($0.17) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Nevro’s earnings. The highest EPS estimate is ($0.02) and the lowest is ($0.37). Nevro posted earnings of ($0.34) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 50%. The firm is expected to report its next quarterly earnings results on Thursday, February 22nd.

According to Zacks, analysts expect that Nevro will report full-year earnings of ($1.27) per share for the current financial year, with EPS estimates ranging from ($1.47) to ($1.12). For the next year, analysts anticipate that the business will post earnings of ($0.50) per share, with EPS estimates ranging from ($1.35) to $0.16. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Nevro.

Nevro (NYSE:NVRO) last announced its quarterly earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.02. Nevro had a negative net margin of 14.09% and a negative return on equity of 17.27%. The company had revenue of $82.26 million during the quarter, compared to analyst estimates of $80.50 million. During the same quarter in the previous year, the business earned ($0.14) EPS. The firm’s revenue was up 35.0% on a year-over-year basis.

Several brokerages have recently issued reports on NVRO. BidaskClub lowered shares of Nevro from a “hold” rating to a “sell” rating in a report on Saturday, October 28th. TheStreet raised shares of Nevro from a “d+” rating to a “c-” rating in a report on Monday, November 6th. BMO Capital Markets reaffirmed a “buy” rating and issued a $100.00 target price on shares of Nevro in a research note on Thursday, December 14th. Northland Securities reaffirmed a “buy” rating and issued a $96.00 target price on shares of Nevro in a research note on Tuesday, November 7th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $110.00 target price (up from $105.00) on shares of Nevro in a research note on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $99.25.

In related news, CFO Andrew H. Galligan sold 7,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $75.11, for a total value of $525,770.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.10% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. Public Employees Retirement System of Ohio acquired a new position in shares of Nevro during the 3rd quarter worth about $636,000. Point72 Asset Management L.P. boosted its stake in shares of Nevro by 35.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,952 shares of the medical equipment provider’s stock worth $49,343,000 after buying an additional 141,963 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Nevro by 27.9% during the 3rd quarter. Jane Street Group LLC now owns 6,655 shares of the medical equipment provider’s stock worth $605,000 after buying an additional 1,450 shares during the last quarter. Royce & Associates LP boosted its stake in shares of Nevro by 71.4% during the 3rd quarter. Royce & Associates LP now owns 24,000 shares of the medical equipment provider’s stock worth $2,181,000 after buying an additional 10,000 shares during the last quarter. Finally, Artisan Partners Limited Partnership boosted its stake in shares of Nevro by 13.2% during the 3rd quarter. Artisan Partners Limited Partnership now owns 433,649 shares of the medical equipment provider’s stock worth $39,410,000 after buying an additional 50,732 shares during the last quarter.

Nevro (NYSE NVRO) opened at $78.64 on Thursday. Nevro has a fifty-two week low of $65.00 and a fifty-two week high of $99.63. The stock has a market cap of $2,330.00, a price-to-earnings ratio of -54.23 and a beta of -0.83. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 6.81.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2018/01/11/1046096.html.

About Nevro

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit